register

News & Trends - MedTech & Diagnostics

Abbott’s world-leading glucose technology TGA registered

Health Industry Hub | March 31, 2021 |

MedTech News: Abbott announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2 is now registered for use in Australia by adults and children (4 and older) with insulin-dependent diabetes, subsequent to review by Australia’s Therapeutic Goods Administration (TGA).

FreeStyle Libre 2, now with automated, optional, real-time glucose alarms, will be made available in Australia over the coming months and will be priced the same as the current FreeStyle Libre system, which is at a fraction of the price of other CGMs (Continuous Glucose Monitors).

“Abbott’s next-generation FreeStyle Libre 2 offers an important choice, with its breakthrough technology and the same price as the popular FreeStyle Libre system” said Peter Chalikias, regional director of Abbott’s diabetes care business in ANZ. “This latest technology is designed to simplify a condition that is not without challenges, and is also accessible to as many people living with diabetes as possible in Australia.”

With FreeStyle Libre 2, more Australians can enjoy features such as unsurpassed 14-day accuracy, excellent performance, trends, insights and actionable data with the FreeStyle LibreLink mobile app10 or on a reader, in a fully disposable device.

Abbott’s FreeStyle Libre 2’s new features such as automated, optional, real-time alarms and ability to measure glucose levels every minute give users the option to be alerted in real-time of critical events such as hypoglycemia (low glucose levels4) or hyperglycemia (high glucose levels).

You may also like Market access and funding key barriers to MedTech innovation, says past President of Stryker Asia-Pacific

The wearable technology, which eliminates the need for painful fingersticks, also provides people with diabetes with unsurpassed 14-day accuracy and actionable information to better manage their condition.

Over the coming months, Abbott will work with the Department of Health to advance the process of including the FreeStyle Libre 2 system on the NDSS. The FreeStyle Libre 2 will be priced the same as the FreeStyle Libre system, which is aimed to ensure equitable and affordable access to this next-generation glucose monitoring technology for more Australians.

FreeStyle Libre 2 stock will be available in the coming months.


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.